ValuEngine cut shares of Benitec Biopharma (NASDAQ:BNTC) from a hold rating to a sell rating in a research report sent to investors on Friday.

Separately, Maxim Group restated a hold rating on shares of Benitec Biopharma in a research report on Wednesday, August 30th.

Shares of Benitec Biopharma (NASDAQ BNTC) traded up $0.13 during midday trading on Friday, reaching $3.03. 13,560 shares of the company traded hands, compared to its average volume of 45,928. Benitec Biopharma has a 12 month low of $1.30 and a 12 month high of $5.48.

COPYRIGHT VIOLATION NOTICE: “Benitec Biopharma (BNTC) Lowered to “Sell” at ValuEngine” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

About Benitec Biopharma

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with's FREE daily email newsletter.